Results
Concord Biotech Approves FY26 Results and ₹7.55 Dividend
Board approved audited standalone and consolidated financial results for Q4 and year ended March 31, 2026, with unmodified audit opinion.
Recommended final dividend of ₹7.55 per equity share with reco
